IVA Stock Price, Analysis & Fundamentals

Analysis

Inventiva S.A. is a biotechnology company operating within the healthcare sector, with a market capitalization of $887.29M and 84 employees. The company's revenue over the past four quarters totals $16.97M. The company has reported gross margin of 95.2%, but its profitability is negatively impacted by a significant net loss of $311,064,992 and an EBITDA of -$95,789,000 over the same period. The operating margin stands at -991.9% and profit margin is 0.0%. Return on Assets (ROA) is -56.8%, indicating substantial losses relative to its assets. The company's balance sheet shows cash reserves of $122.51M and debt of $132.80M, resulting in a current ratio of 2.96. The valuation of Inventiva S.A. is indicated by a forward P/E of -3.19, price to book of -61.41, and EV/EBITDA of -7.02. The company's revenue growth over the past year was 105.2%, while earnings growth is not available.

This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.

About Inventiva S.A.

Inventiva S.A., a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) and other diseases in France and internationally. The company develops Lanifibranor, a novel pan-peroxisome proliferator-activated receptor agonist that is in the NATiV3 Phase 3 clinical trial to treat adult patients with MASH; and Odiparcil for the treatment of patients with mucopolysaccharidoses. It also develops TGF-ß, a pre-clinical program for the treatment of idiopathic pulmonary fibrosis. The company was incorporated in 2011 and is headquartered in Daix, France.

Visit website →

IVA

Price History (1Y)

Analysis

About Inventiva S.A.

Key Statistics

Company Info